Adakveo (crizanlizumab)

£5,214.38

Adakveo (crizanlizumab) is a medication used to prevent painful crises in patients with sickle cell disease aged 16 years and older.

It is the first targeted therapy approved for sickle cell disease.

DISEASE INDICATIONS

Sickle Cell Disease

MANUFACTURER

Novartis

USAGE

Intravenous

MEDICINE APPROVED BY

  • European Medical Agency (EMA)

  • Food and Drug Administration (FDA)

    PATIENTS HELPED

    • Over 1.2 million patients reached

    • More than 11,000 patients helped

    • 100% successful deliveries to 88 countries

This content has been reviewed by a Medical Doctor.
ADAKVEO (CRIZANLIZUMAB) Package

100 mg/10 ml

Reviews

There are no reviews yet.

Be the first to review “Adakveo (crizanlizumab)”

Your email address will not be published. Required fields are marked *

Shopping Cart